
Genentech Reports Positive Phase III Results for Gazyva in Youth Nephrotic Syndrome
Genentech Reports Positive Phase III Results for Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced statistically significant and clinically meaningful findings from its Phase…








